25/100B40.640
USD
-0.02
(-0.05%)
Market Open
Last updated: · Delayed 15 min
Roivant Sciences operating income 2019–2026What are gross, operating and net profit margins? A profit margin is the share of revenue kept as profit: gross margin after the cost of sales, operating margin after running costs, net margin after all costs.
Roivant Sciences's operating income in Q2 FY2026, the three months to 30 September 2026, was -268.05M USD, against a loss of 306.23M USD on the same quarter a year before. Roivant Sciences's operating income in fiscal year 2025 was -1.29B USD, against a loss of 1.11B USD on the year before.
Last updated 10 Nov 2026 · Next report 5 Feb 2027
Operating income
Operating income Operating margin
| Fiscal year | Period ending | Operating income | Growth | Operating margin | Gross profit | Gross margin | EBITDA |
|---|---|---|---|---|---|---|---|
| TTM | 30 Sept 2026 | -1.33B | — | -3,233.02% | 36.43M | 88.68% | -294.65M |
| FY2025 | 31 Mar 2026 | -1.29B | — | -15,560.57% | 6.98M | 84.44% | -261.23M |
| FY2024 | 31 Mar 2025 | -1.11B | — | -3,833.27% | 28.14M | 96.86% | -667.52M |
| FY2023 | 31 Mar 2024 | -824.93M | — | -2,521.71% | 31.11M | 95.11% | 4.62B |
| FY2022 | 31 Mar 2023 | -809.01M | — | -2,565.85% | 28.50M | 90.38% | -838.17M |
| FY2021 | 31 Mar 2022 | -1.21B | — | -2,191.78% | 46.32M | 83.78% | -910.77M |
| FY2020 | 31 Mar 2021 | -1.07B | — | -4,500.52% | 21.74M | 91.36% | -895.74M |
| FY2019 | 31 Mar 2020 | -532.43M | — | -786.58% | 66.56M | 98.33% | -553.30M |
| Quarter | Period ending | Operating income | Growth on a year before | Operating margin | Gross profit | Gross margin | EBITDA |
|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 30 Sept 2026 | -268.05M | — | -763.22% | 31.77M | 90.47% | -165.74M |
| Q1 FY2026 | 30 Jun 2026 | -365.99M | — | -25,380.93% | 1.16M | 80.31% | -293.96M |
| Q4 FY2025 | 31 Mar 2026 | -355.00M | — | -14,087.10% | 2.20M | 87.30% | 454.74M |
| Q3 FY2025 | 31 Dec 2025 | -339.15M | — | -16,966.13% | 1.30M | 64.98% | -289.68M |
| Q2 FY2025 | 30 Sept 2025 | -306.23M | — | -19,492.87% | 1.46M | 92.93% | -158.12M |
| Q1 FY2025 | 30 Jun 2025 | -284.92M | — | -13,130.05% | 2.02M | 92.90% | -268.16M |
| Q4 FY2024 | 31 Mar 2025 | -284.97M | — | -3,764.40% | 7.37M | 97.29% | -201.63M |
| Q3 FY2024 | 31 Dec 2024 | -274.38M | -105.35% | -3,042.59% | 8.76M | 97.13% | -231.59M |
| Q2 FY2024 | 17 Sept 2024 | -341.71M | — | -7,636.04% | 4.24M | 94.77% | -219.54M |
| Q1 FY2024 | 30 Jun 2024 | -102.24M | — | -1,279.54% | 7.78M | 97.33% | -207.74M |
| Q4 FY2023 | 31 Mar 2024 | -266.00M | — | -919.46% | 24.52M | 84.75% | -182.23M |
| Q3 FY2023 | 31 Dec 2023 | 5.13B | — | 32,948.56% | 15.37M | 98.73% | -215.57M |
| Q2 FY2023 | 30 Sept 2023 | -213.89M | — | -5,863.24% | 3.43M | 93.89% | -192.66M |
| Q1 FY2023 | 30 Jun 2023 | -276.41M | — | -1,278.27% | 17.41M | 80.51% | -311.34M |
| Q4 FY2022 | 31 Mar 2023 | -234.17M | — | -855.37% | 17.99M | 65.71% | -163.13M |
| Q3 FY2022 | 31 Dec 2022 | -280.33M | — | -1,643.96% | 8.73M | 51.18% | -366.67M |
Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.
See also:Revenue,Net income,EPS,Shares outstanding,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement
Common questions about Roivant Sciences's operating income
Source: Financial Modeling Prep